Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (1y) (2014 - 2025)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Cash from Investing Activities Growth (1y) (2014 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 91.53% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -41.67% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -6,635.44% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -89.24% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 129.68% |
| Mar 31, 2025 | 121.13% |
| Dec 31, 2024 | 830.20% |
| Sep 30, 2024 | 158.74% |
| Jun 30, 2024 | -545.38% |
| Mar 31, 2024 | -174.11% |
| Dec 31, 2023 | 94.97% |
| Sep 30, 2023 | -1,272.04% |
| Dec 31, 2022 | -904.84% |
| Sep 30, 2022 | 50.17% |
| Dec 31, 2021 | 127.56% |
| Sep 30, 2021 | -84,787.50% |
| Jun 30, 2021 | -53.60% |
| Mar 31, 2021 | 774.94% |
| Dec 31, 2020 | -46,990.00% |
| Jun 30, 2020 | 5,031.07% |
| Mar 31, 2020 | -196.41% |
| Dec 31, 2019 | -100.35% |
| Jun 30, 2019 | -110.07% |
| Mar 31, 2019 | -95.51% |